Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMN HEALTHCARE SERVICES INCAMN · Entity 4780 | Director | June 15, 2026 | June 17, 2026 |
| DEXCOM INCDXCM · Entity 3114 | Director | July 31, 2026 | August 04, 2026 |
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director | March 11, 2026 | March 13, 2026 |
| Forte Biosciences, Inc.TOCA · Entity 9529 | EVP & Chief Financial Officer | October 04, 2019 | October 05, 2019 |
| Regulus Therapeutics Inc.RGLS · Entity 78034 | Director | December 04, 2017 | December 07, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMN HEALTHCARE SERVICES INC
Report date June 15, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 17,917 |
Last balance in matching sequence
After 2026-06-15 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-06-15 · Sale · Disposed 1,681 · Balance 19,917 F1: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F2: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Row 2 · 2026-06-15 · Sale · Disposed 2,000 · Balance 17,917 F4: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F5: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan").
F2: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
F4: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan").
F5: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
DEXCOM INC
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 48,852 |
Last balance in matching sequence
After 2026-08-03 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-31 · Sale · Disposed 2,000 · Balance 50,852 F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Row 2 · 2026-08-03 · Sale · Disposed 2,000 · Balance 48,852 F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 6,331 |
Reported balance
Holding disclosure · report date 2026-07-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6,331 F3: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
F2: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
F3: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.
ENANTA PHARMACEUTICALS INC
Report date March 11, 2026 · Filed March 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11 | Direct | 20,000 |
Reported balance
After 2026-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
Forte Biosciences, Inc.
Report date October 04, 2019 · Filed October 05, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.64 · Expires 2029-10-03 | Direct | 30,000 |
Reported balance
After 2019-10-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-04 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares vest in a series of twelve (12) successive equal monthly installments measured from October 3, 2019.
Regulus Therapeutics Inc.
Report date December 04, 2017 · Filed December 07, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 81,910 |
Reported balance
After 2017-12-04 transaction · row 1
1 source rowRow 1 · 2017-12-04 · Grant · Acquired 71,910 · Balance 81,910 F1: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units (RSUs) issued in lieu of 2018 annual retainer and meeting fees of $64,000. The RSUs vest ratably on a quarterly basis on the last day of each calendar quarter in 2018, subject to the reporting person's continuous service to Regulus.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 4, 2026 20:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,000 | $85.32 | $170,640.00 |
DisclosureSEC source: 0001093557-26-000145 · wk-form4_1785875897.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 48,852 F1 · shares: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Read SEC document |
| July 31, 2026 Filed Aug 4, 2026 20:38 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,000 | $80.00 | $160,000.00 |
DisclosureSEC source: 0001093557-26-000145 · wk-form4_1785875897.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 50,852 F1 · shares: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 199 | $74.82 | $14,888.92 |
DisclosureSEC source: 0001093557-26-000130 · wk-form4_1781728340.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 52,852 F1 · shares: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:32 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,801 | $74.10 | $281,650.68 |
DisclosureSEC source: 0001093557-26-000130 · wk-form4_1781728340.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 53,051 F1 · shares: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 11:31 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | SaleCommon Stock | 2,000 | $31.07 | $62,138.00 |
DisclosureSEC source: 0001628280-26-043718 · wk-form4_1781695915.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 17,917 F4 · kind: The sale of 2,000 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F5 · price: The price reported in this row represents a weighted average price of $31.069 per share. These shares were sold in multiple transactions at prices ranging from $30.82 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 11:31 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | SaleCommon Stock | 1,681 | $31.07 | $52,223.63 |
DisclosureSEC source: 0001628280-26-043718 · wk-form4_1781695915.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 19,917 F1 · kind: The sale of 1,681 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026 (the "Trading Plan"). F2 · price: The price reported in this row represents a weighted average price of $31.067 per share. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.22, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 21:34 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 6,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000122 · wk-form4_1780349691.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,331 F1 · shares: The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Read SEC document |
| May 08, 2026 Filed May 11, 2026 23:13 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 5,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000079 · wk-form4_1778541186.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 56,852 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| May 08, 2026 Filed May 11, 2026 23:13 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 5,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-26-000079 · wk-form4_1778541186.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:35 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | GrantRestricted Stock Units · Derivative | 8,304 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-029865 · wk-form4_1777926930.xml · derivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,304 Underlying: Common Stock · 8,304 shares Expires not disclosed F5 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2025 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F6 · derivative.exercise_date: The RSUs identified in this row were granted on May 1, 2026 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2027. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:35 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionRestricted Stock Units · Derivative | 8,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-029865 · wk-form4_1777926930.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock F3 · derivative.exercise_date: The RSUs identified in this row were granted on May 2, 2025 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2026. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| May 01, 2026 Filed May 4, 2026 20:35 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionCommon Stock | 8,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-029865 · wk-form4_1777926930.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,598 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| March 11, 2026 Filed Mar 13, 2026 20:15 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0002064832-26-000139 · form4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-03-11 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 195 | $81.54 | $15,900.30 |
DisclosureSEC source: 0001093557-25-000245 · wk-form4_1755553988.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 51,121 F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the reporting person is a trustee. Read SEC document |
| August 15, 2025 Filed Aug 18, 2025 21:53 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,555 | $81.02 | $207,002.52 |
DisclosureSEC source: 0001093557-25-000245 · wk-form4_1755553988.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 51,316 F1 · shares: On March 13, 2025, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $80.29 to $81.22. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 8 | $86.03 | $688.24 |
DisclosureSEC source: 0001093557-25-000228 · wk-form4_1752782910.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 53,871 F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the reporting person is a trustee. Read SEC document |
| July 15, 2025 Filed Jul 17, 2025 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,742 | $85.17 | $233,528.46 |
DisclosureSEC source: 0001093557-25-000228 · wk-form4_1752782910.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 53,879 F1 · shares: On March 13, 2025, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $84.815 to $85.44. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:31 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,750 | $83.13 | $228,604.75 |
DisclosureSEC source: 0001093557-25-000218 · wk-form4_1750278712.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 56,621 F1 · shares: On March 13, 2025, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $82.635 to $83.61. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · ownership.nature: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the reporting person is a trustee. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 5,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000149 · wk-form4_1747080470.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,731 F3 · shares: The RSU Award was granted on May 8, 2025 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2026 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 2,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000149 · wk-form4_1747080470.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 59,371 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F2 · ownership.nature: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| May 08, 2025 Filed May 12, 2025 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 2,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-25-000149 · wk-form4_1747080470.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 02, 2025 Filed May 6, 2025 16:47 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | GrantRestricted Stock Units · Derivative | 8,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001142750-25-000028 · wk-form4_1746550025.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires not disclosed F1 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock F2 · derivative.exercise_date: The RSUs identified in this row were granted on May 2, 2025 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2026. F3 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| April 19, 2025 Filed Apr 21, 2025 22:07 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionRestricted Stock Units · Derivative | 3,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001142750-25-000017 · wk-form4_1745273243.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,019 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F3 · derivative.exercise_date: The RSUs identified in this row were granted on April 19, 2024 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2025. Accordingly, the number of RSUs identified in this row vested on April 19, 2025. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| April 19, 2025 Filed Apr 21, 2025 22:07 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionCommon Stock | 3,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001142750-25-000017 · wk-form4_1745273243.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,273 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 21:34 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001062993-25-005503 · form4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2035-03-13 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 299 | $117.25 | $35,056.40 |
DisclosureSEC source: 0001093557-24-000133 · edgardoc.xml · nonDerivative · entry 5 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 56,398 F1 · shares: On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F6 · price: This transaction was executed in multiple trades at prices ranging from $117.235 to $117.26. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 3,007 | $116.75 | $351,065.15 |
DisclosureSEC source: 0001093557-24-000133 · edgardoc.xml · nonDerivative · entry 4 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 56,697 F1 · shares: On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $116.265 to $117.195. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 475 | $117.77 | $55,941.56 |
DisclosureSEC source: 0001093557-24-000133 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 59,704 F1 · shares: On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $117.61 to $117.83. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 2,212 | $117.16 | $259,159.47 |
DisclosureSEC source: 0001093557-24-000133 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 60,179 F1 · shares: On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $116.76 to $117.60. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:50 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 7 | $115.18 | $806.26 |
DisclosureSEC source: 0001093557-24-000133 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Plan reported Ownership: Indirect · by Trust Disclosed balance after: 62,391 F1 · shares: On March 15, 2024, the Foletta Family Trust DTD 1/30/15 (the ?Trust?) adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| May 22, 2024 Filed May 24, 2024 21:40 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 2,973 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000116 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,973 F1 · shares: The RSU Award was granted on May 22, 2024 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2025 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Read SEC document |
| May 18, 2024 Filed May 21, 2024 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 3,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000095 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 62,398 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F2 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| May 18, 2024 Filed May 21, 2024 20:08 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 3,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000095 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 19:25 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | GrantRestricted Stock Units · Derivative | 3,019 | $0.00 | $0.00 |
DisclosureSEC source: 0001142750-24-000032 · wk-form4_1713900303.xml · derivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,019 Underlying: Common Stock · 3,019 shares Expires not disclosed F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F5 · derivative.exercise_date: The RSUs identified in this row were granted on April 19, 2024 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2025. Accordingly, the number of RSUs identified in this row vested on April 19, 2024. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 19:25 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionRestricted Stock Units · Derivative | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001142750-24-000032 · wk-form4_1713900303.xml · derivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F3 · derivative.exercise_date: The RSUs identified in this row were granted on May 17, 2023 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2024. F4 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| April 19, 2024 Filed Apr 23, 2024 19:25 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionCommon Stock | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001142750-24-000032 · wk-form4_1713900303.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:15 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $15.66 | $0.00 |
DisclosureSEC source: 0001062993-24-006038 · form4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-03-06 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders. Read SEC document |
| February 29, 2024 Filed Mar 1, 2024 20:57 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | PurchaseCommon Stock | 500 | $56.90 | $28,450.00 |
DisclosureSEC source: 0001142750-24-000024 · wk-form4_1709326663.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,573 Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:49 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 4,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-23-000139 · edgardoc.xml · nonDerivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · by Trust Disclosed balance after: 59,092 F2 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. F3 · balance_after: Shares are held by the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, with respect to which the reporting person is a trustee. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:49 UTC | DEXCOM INC DXCM · Entity 3114 | GiftCommon Stock | 4,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-23-000139 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,306 F2 · shares: Shares were transferred from direct ownership to ownership under the Mark G. and Mary E. Foletta, TTEE's for the Foletta Family Trust DTD 1/30/15, upon vesting of previously awarded restricted stock units. Read SEC document |
| May 18, 2023 Filed May 22, 2023 19:49 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 3,306 | $0.00 | $3.31 |
DisclosureSEC source: 0001093557-23-000139 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,794 F1 · shares: The RSU Award was granted on May 18, 2023 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2024 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Read SEC document |
| May 17, 2023 Filed May 19, 2023 21:35 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionRestricted Stock Units · Derivative | 1,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031160 · doc4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,681 Underlying: Common Stock · 1,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F2 · derivative.exercise_date: The RSUs identified in this row were granted on May 17, 2023 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2024. F3 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:05 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionRestricted Stock Units · Derivative | 1,458 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025606 · doc4.xml · derivative · entry 3 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,458 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The RSUs were granted pursuant to the AMN Healthcare 2017 Equity Plan. Each RSU represents a contingent right to receive one share of AMN Common Stock. F5 · derivative.exercise_date: The RSUs identified in this row were granted on April 21, 2022 and vest on the earlier of (i) the one year anniversary of the grant date, or (ii) the date of the Company's Annual Meeting of Shareholders in 2023, which will be held on May 17, 2023. Accordingly, the number of RSUs identified in this row vested on April 21, 2023. F6 · derivative.expiration_date: RSUs do not have an expiration date. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:05 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | SaleCommon Stock | 1,458 | $88.78 | $129,441.24 |
DisclosureSEC source: 0001209191-23-025606 · doc4.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,073 F2 · kind: The sale of 1,458 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in this row represents a weighted average price of $88.78 per share. These shares were sold in multiple transactions at prices ranging from $88.43 to $89.08, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2023 Filed Apr 25, 2023 22:05 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | Exercise / conversionCommon Stock | 1,458 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025606 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: AMN Common Stock acquired on the vesting of Restricted Stock Units ("RSUs"). Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 20:52 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | SaleCommon Stock | 1,053 | $84.63 | $89,115.39 |
DisclosureSEC source: 0001209191-23-024223 · doc4.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,073 F3 · kind: The sale of 1,053 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in this row represents a weighted average price of $84.63 per share. These shares were sold in multiple transactions at prices ranging from $84.56 to $84.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 20:52 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | SaleCommon Stock | 4,989 | $84.29 | $420,522.81 |
DisclosureSEC source: 0001209191-23-024223 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,126 F1 · kind: The sale of 4,989 shares of AMN Common Stock was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in this row represents a weighted average price of $84.29 per share. These shares were sold in multiple transactions at prices ranging from $83.535 to $84.535, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:16 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 10,800 | $0.00 Strike: $47.72 | $0.00 |
DisclosureSEC source: 0001062993-23-006089 · form4.xml · derivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2033-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2023), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2024 annual meeting of stockholders. Read SEC document |
| November 15, 2022 Filed Dec 16, 2022 22:30 UTC | AMN HEALTHCARE SERVICES INC AMN · Entity 4780 | GiftCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061721 · doc4.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,115 F1 · kind: The Reporting Person transferred 300 shares of AMN Common Stock as a gift to charity. Read SEC document |
| May 20, 2022 Filed May 23, 2022 21:05 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 1,122 | $0.00 | $1.12 |
DisclosureSEC source: 0001093557-22-000117 · edgardoc.xml · nonDerivative · entry 2 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,122 F2 · shares: The RSU Award was granted on May 20, 2022 and 100% of the RSU will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. F3 · balance_after: Represents 1,122 restricted stock units which were granted on May 20, 2022 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom Inc's 2023 Annual Meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.